New RWD company CuriMeta partners with BJC HealthCare and Washington University School of Medicine in St Louis

A new company CuriMeta will curate and enhance the value of RWD to empower researchers, advised by partners BJC HealthCare and Washington University School of Medicine in St Louis.

Washington University School of Medicine in St Louis (WashU Medicine) and BJC HealthCare are partnering to collaborate with RWD company CuriMeta. CuriMeta’s remit is to empower researchers and accelerate healthcare research with advanced, de-identified and aggregated RWD.

WashU Medicine and BJC Healthcare will advise CuriMeta on establishing strategic partnerships for RWD studies to target key gaps in evidence and insights and propel promising research across a diverse set of diseases. David H Perlmutter, MD, WashU Medicine Executive Vice Chancellor for medical affairs and Dean of the School of Medicine said, “We will assist CuriMeta in identifying and vetting research opportunities with appropriate life science companies. Few health care institutions have the breadth and depth of clinical research resources of WashU Medicine and BJC to bring about this kind of big data endeavor.”

CuriMeta’s medical data experts will analyze, expand, organize and aggregate RWD from their partners into multiple secure privacy-protecting datasets. “We are investing significantly in augmenting and improving the usefulness of the data, not just gathering it,” said Davis Walp, CuriMeta Founder and Chief Executive Officer. “Our data experts will curate, harmonize, and apply machine learning techniques to enhance the quality, completeness, and research value of our collaborators’ data.” Patient confidentiality will be protected beyond current legally required safeguards using cutting-edge technology, such as artificial intelligence to create ‘synthetic data’ sets: these are computationally generated health data that statistically replicate actual de-identified, aggregated health data, but have no direct relationship to individual patient records.

Engaging with life science collaborators focused on identifying new insights into cancer, cardiovascular disease, neurodegenerative diseases and other neurological conditions, as well as rare diseases and childhood illnesses — all clinical strengths at WashU Medicine and BJC HealthCare — will be a major emphasis for CuriMeta. “We have the tools to shape our future” said Richard J Liekweg, President and Chief Executive Officer of BJC HealthCare. “It’s our responsibility to use this unparalleled data platform to chart elusive territory where curing, preventing and predicting deadly or chronic illness is possible.”